Orforglipron
Overview
Orforglipron is a non-peptide, oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist designed to overcome the need for injectable delivery. It activates the GLP-1 receptor to enhance glucose-dependent insulin secretion, suppress glucagon release, and slow gastric emptying. The therapeutic rationale centers on improving adherence in type 2 diabetes and obesity management by providing once-daily oral dosing as an alternative to injectable GLP-1 receptor agonists.
Key Research Findings
Phase 2 trials have demonstrated dose-dependent reductions in HbA1c and body weight in adults with type 2 diabetes, with results presented at major diabetes conferences in 2023. Gastrointestinal adverse events were consistent with the GLP-1 agonist class. Phase 3 development is ongoing to establish efficacy and safety in broader patient populations.
Oral
In Clinical Trials
Interested in Orforglipron?
Find a verified provider experienced with Orforglipron protocols in your area. All providers are credentialed and use compliant sourcing.
Find a Orforglipron ProviderRelated Peptides
Semaglutide (Ozempic/Wegovy)
FDA ApprovedA glucagon-like peptide-1 receptor agonist (GLP-1 RA) with 94% amino acid homology to native GLP-1. Semaglutide enhances glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and acts on hypothalamic GLP-1 receptors to reduce appetite. Its fatty acid side chain enables albumin binding, extending its half-life to approximately 7 days.
Tirzepatide (Mounjaro/Zepbound)
FDA ApprovedA first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activates both incretin pathways simultaneously, producing superior glycemic control and weight loss compared to selective GLP-1 RAs. The dual mechanism enhances insulin sensitivity and lipid metabolism beyond what either pathway achieves alone.
Retatrutide
In Clinical TrialsAn investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The glucagon receptor component adds thermogenic energy expenditure and hepatic lipid mobilization to the incretin-mediated appetite suppression and insulin sensitization. This triple mechanism addresses obesity through complementary metabolic pathways.
AOD-9604
InvestigationalA modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine at the N-terminus. AOD-9604 retains the lipolytic activity of hGH without its growth-promoting or diabetogenic effects. It stimulates lipolysis and inhibits lipogenesis through a mechanism distinct from the GH receptor, acting on beta-3 adrenergic receptors in adipose tissue.